Cargando…
Association of human myxovirus resistance protein A with severity of COVID-19
BACKGROUND: In this retrospective cohort study, we explored the correlation of blood human myxovirus resistance protein A (MxA) level with severity of disease in hospitalized COVID-19 patients. METHODS: All 304 patients admitted for COVID-19 in our hospital until 30th of April 2021 were included in...
Autores principales: | Lehtinen, Otto, Broman, Niklas, Waris, Matti, Vuorinen, Tytti, Peltola, Ville, Löyttyniemi, Eliisa, Oksi, Jarmo, Feuth, Thijs |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517979/ https://www.ncbi.nlm.nih.gov/pubmed/36171547 http://dx.doi.org/10.1186/s12879-022-07753-0 |
Ejemplares similares
-
Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM—a prospective, randomized, single-centre, open-label study
por: Broman, Niklas, et al.
Publicado: (2022) -
Aetiology of febrile pharyngitis in children: Potential of myxovirus resistance protein A (MxA) as a biomarker of viral infection
por: Ivaska, Lauri, et al.
Publicado: (2017) -
‘Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM’ – Author's reply
por: Broman, Niklas, et al.
Publicado: (2022) -
Myxovirus Resistance Protein A as a Marker of Viral Cause of Illness in Children Hospitalized with an Acute Infection
por: Piri, Ruut, et al.
Publicado: (2022) -
IL-6 and other biomarkers as predictors of severity in COVID-19
por: Broman, N., et al.
Publicado: (2021)